

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Nursing Research; Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: National Institute of Nursing Research Initial Review Group.

Date: February 26–27, 1998.

Time: 8:30 a.m. until adjournment.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: Mary Stephens-Frazier, Ph.D., Building 45, Room 3AN-18, 45 Center Drive, Bethesda, MD 20892, (301) 594-5971.

Purpose/Agenda: To review and evaluate grant applications.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.361, Nursing Research, National Institutes of Health)

Dated: January 6, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-906 Filed 1-13-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Warren Grant Magnuson Clinical Center; Meeting of the Board of Governors

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Board of Governors of the Warren Grant Magnuson Clinical Center, January 23, 1998. The Board of Governors will meet at the National Institutes of Health, Clinical Center (Building 10), Medical Board Room (2C116), 9000 Rockville Pike, Bethesda, Maryland, from 9:00 a.m. until approximately 12:00 p.m.

The meeting will be open to the public from 9:00 a.m. to 11:30 a.m. and will include review of the minutes of the December 1, 1997 Executive Committee meeting, membership rotation schedule, updates on the

Budget and Strategic Planning, and the Director's Annual Report.

In accordance with the provisions set forth in section 552b(c)(6) of Title 5, U.S.C. and section 10(d) of Public Law 92-463, the meeting will be closed to the public from approximately 11:30 a.m. to adjournment for discussion of personnel qualifications and performance of the Director, Clinical Center, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Attendance by the public will be limited to space available.

For further information, contact Ms. Maggi Stakem, Office of the Director, Warren Grant Magnuson Clinical Center, Building 10, Room 2C146, Bethesda, Maryland 20892, (301) 496-4114.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Stakem in advance of the meeting.

This notice is being published less than fifteen days prior to this meeting due to scheduling conflicts.

Dated: January 7, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-893 Filed 1-13-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program; Board of Scientific Counselors' Meeting

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the National Toxicology Program (NTP) Board of Scientific Counselors, U.S. Public Health Service, in the Conference Center, Building 101, South Campus, National Institute of Environmental Health Sciences (NIEHS), 111 Alexander Drive, Research Triangle Park, North Carolina, on February 5 and 6, 1998.

Agenda

The meeting will be open to the public from 8:45 a.m. to 4:00 p.m. on February 5, and from 8:45 a.m. to adjournment on February 6, with attendance limited only by space available. The primary agenda topic on February 5 will be a comprehensive evaluation of the strategies for use of transgenic mouse models in bioassays for carcinogenesis. Included will be an introduction, history and rationale for using transgenic animals to identify

carcinogens, sharing of results from three mouse models—p53^{def}, Tg.AC, and *rasH2*—, NTP strategies for evaluating models, utility of transgenic model results for risk assessment, and regulatory agency perspectives. There are four issues that the Board will be asked to advise the NTP on, being: (1) Is the NTP approach to evaluation and validation of transgenic models for use in cancer bioassays sufficient and appropriate?; (2) How can existing models be best utilized? What are their limitations?; (3) What new models are needed, i.e., should the NTP seek to develop organ-specific tumor models; and (4) Are the scientific needs of regulatory agencies being adequately addressed? Background materials pertaining to the evaluation of transgenic models will be available on request from the Executive Secretary after January 12, 1998.

Among several agenda topics on February 6 will be a discussion of and opportunity for public comment on chemicals nominated for NTP studies that were reviewed by the NTP Interagency Committee for Chemical Evaluation and Coordination on August 15, 1997, and December 11, 1997. The Committee recommended nine chemicals and four mixtures for toxicological studies, recommended four chemicals be deferred for additional information, and recommended six chemicals not be studied. The chemicals/classes with CAS Nos. in parentheses are—*Recommended for Study:* (1) 2-Acetylpyridine (1122-62-9); (2) Asphalt Fumes (8052-42-4); (3) 2-Chloropyridine (109-09-1); (4) Comfrey (72698-57-8) with Symphytine (22571-95-5); (5) Glycoluril (496-46-8); (6) Goldenseal (—) containing Berberine (2086-83-1) and Hydrastine (118-08-1); (7) Luminol (o-Aminophthalic Hydrazide) (521-31-3); (8) 4-Methoxy-N-methyl-1,8-naphthalimide (3271-05-4); (9) Myristicin (607-91-0); (10) 7-(2H-Naphthol[1,2-d] triazol-2-yl)-3-phenylcoumarin; (11) Orphanic Acid (88-21-1); (12) Phenothiazine (92-84-2); and (13) Saw Palmetto containing β -Sitosterol (83-46-5). The chemicals for which *No Study is Recommended* are: (1) *trans*-1,4-Dichloro-2-butene; (2) Dicyclopentadiene (77-73-6); (3) C.I. Direct Black 80 (8003-69-8); (4) Ethyl Cyanoacrylate (7085-85-0); (5) Isoamyl Acetate; and (6) 2,4,6-Tribromophenol. *Chemicals Deferred for Additional Information* are: (1) 3-Amino-5-mercapto-1,2,4-triazole (16691-43-3); (2) Diethylamine (109-89-7); (3) Isopropylamine (75-31-0); and (4) Triethylamine (121-44-8).